Current strategies for treatment of relapsed/refractory multiple myeloma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current strategies for treatment of relapsed/refractory multiple myeloma
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 7, Issue 1, Pages 97-111
Publisher
Informa UK Limited
Online
2014-01-29
DOI
10.1586/17474086.2014.882764
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Salvage Second Hematopoietic Cell Transplantation in Myeloma
- (2013) Laura C. Michaelis et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
- (2013) M. Wang et al. BLOOD
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
- (2013) Maria T. Petrucci et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
- (2013) M. A. Dimopoulos et al. HAEMATOLOGICA
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
- (2013) A Z Badros et al. LEUKEMIA
- Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation
- (2013) Holger W. Auner et al. LEUKEMIA & LYMPHOMA
- Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma
- (2012) Emilie Lemieux et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
- (2012) D. S. Siegel et al. BLOOD
- Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
- (2012) P. G. Richardson et al. BLOOD
- Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
- (2012) L. Santo et al. BLOOD
- Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
- (2012) J. B. Egan et al. BLOOD
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
- (2012) M. Cavo et al. BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT
- (2012) H-Y Yhim et al. BONE MARROW TRANSPLANTATION
- Second auto-SCT for treatment of relapsed multiple myeloma
- (2012) W I Gonsalves et al. BONE MARROW TRANSPLANTATION
- Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma
- (2012) Neil Rabin et al. BRITISH JOURNAL OF HAEMATOLOGY
- Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
- (2012) Matthew Hoffmann et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
- (2012) Donna M. Weber et al. Clinical Lymphoma Myeloma & Leukemia
- Successful Treatment of Patients With Multiple Myeloma and Impaired Renal Function With Lenalidomide: Results of 4 German Centers
- (2012) Katharina Oehrlein et al. Clinical Lymphoma Myeloma & Leukemia
- Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2012) Laurent Garderet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Exome sequencing in tracking clonal evolution in multiple myeloma following therapy
- (2012) N Weston-Bell et al. LEUKEMIA
- The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
- (2012) M A Dimopoulos et al. LEUKEMIA
- Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma
- (2012) Jeffrey L. Wolf et al. LEUKEMIA & LYMPHOMA
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
- (2011) Victor H. Jimenez-Zepeda et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
- (2011) M. Q. Lacy et al. BLOOD
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
- (2011) S. V. Rajkumar et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
- (2011) Ticiana B. Leal et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
- (2011) E. C. Lee et al. CLINICAL CANCER RESEARCH
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells
- (2011) Dharminder Chauhan et al. CLINICAL CANCER RESEARCH
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Pomalidomide therapy for myeloma
- (2011) Stephen Schey et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Management of treatment-emergent peripheral neuropathy in multiple myeloma
- (2011) P G Richardson et al. LEUKEMIA
- Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation
- (2011) Roland Fenk et al. LEUKEMIA & LYMPHOMA
- Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
- (2010) Sung Sook Lee et al. ANNALS OF HEMATOLOGY
- Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
- (2010) Ulrike Klein et al. ANNALS OF HEMATOLOGY
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma
- (2010) D. Chauhan et al. BLOOD
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
- (2010) P. G. Richardson et al. BLOOD
- Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
- (2010) A. Broyl et al. BLOOD
- The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study
- (2010) Stephen A. Schey et al. BRITISH JOURNAL OF HAEMATOLOGY
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
- (2010) Meletios Dimopoulos et al. CANCER
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study
- (2010) Heinz Ludwig et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
- (2010) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
- (2010) Michel Delforge et al. LANCET ONCOLOGY
- Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma
- (2010) A Palumbo et al. LEUKEMIA
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520
- (2010) B. J. Tunquist et al. MOLECULAR CANCER THERAPEUTICS
- Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
- (2009) P. Richardson et al. BLOOD
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
- (2009) Paul G. Richardson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- (2009) E. M. Ocio et al. HAEMATOLOGICA
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy
- (2009) Paul G. Richardson et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure
- (2009) Andrew Spencer et al. JOURNAL OF CLINICAL ONCOLOGY
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
- (2009) Asher Chanan-Khan et al. LEUKEMIA & LYMPHOMA
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE
- (2008) Muralikrishnan Srikanth et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma
- (2008) Marie von Lilienfeld-Toal et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma
- (2008) Donna E. Reece et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
- (2008) Olivier Decaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now